[{"from": "human", "value": "Could you provide a description of this molecule? [C][C@H1][C][O][C][C][N][Ring1][=Branch1][C][=N][C][=C][Branch2][Ring1][=Branch2][C][=C][C][=Branch1][Ring2][=N][Ring1][=Branch1][C][=C][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][C][=Branch1][C][=O][N][C][C][=Branch1][Branch1][=N][Ring2][Ring1][Ring2][N][C][C][C][C][Ring1][Branch1][C][O][C][Ring1][#Branch1]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 inhibitor LXI-15029 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy."}]